NCT06953843RecruitingPhase 2
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
An Umbrella Trial of Combining Different Radiotherapy Fractionation Patterns With Immunotherapy for Multiple Metastases of Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 14 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 366 (estimated)
- First submitted
- 20 Apr 2025
- Start date
- 9 Jul 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Diseases
- Lung cancer
- NCT number
- NCT06953843
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 366
- From 9 Jul 2025 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any of the following criteria are not eligible for enrollment in this study:
- Those with severe dysfunction of important vital organs (heart, liver, kidney).
- Those accompanied by other malignant tumors.
- Uncontrolled heart diseases or myocardial infarction within the past 6 months.
- Those with a history of mental illness.
- Other situations in which the researcher deems it inappropriate for the subject to participate in the study.
Who the study is looking for
- Patient must meet all of the following inclusion criteria to be enrolled in this study:
- Non-small cell lung cancer confirmed by pathological histology.
- More than 3 metastatic lesions.
- No brain metastases or stable lesions.
- Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).
- Performance status (PS) score of 0-1, with an expected survival period of more than 3 months.
- Age between 18 and 75 years old.
- Assessment by PET-CT (including FDG and FMISO, not mandatory).
- No contraindications to immunotherapy and radiotherapy.
- Signed the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the second affiliated hospital of Army medical university Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.